Theseus Pharmaceuticals, Inc.

NASDAQ:THRX

4.06 (USD) • At close February 13, 2024
Bedrijfsnaam Theseus Pharmaceuticals, Inc.
Symbool THRX
Munteenheid USD
Prijs 4.065
Beurswaarde 181,498,998
Dividendpercentage 0%
52-weken bereik 2.05 - 12.37
Industrie Biotechnology
Sector Healthcare
CEO Dr. Timothy P. Clackson Ph.D.
Website https://theseusrx.com

An error occurred while fetching data.

Over Theseus Pharmaceuticals, Inc.

Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors, which is in Phase I clinical trial. The company also develops fourth-generation

Vergelijkbare Aandelen

Akero Therapeutics, Inc. logo

Akero Therapeutics, Inc.

AKRO

26.96 USD

Icosavax, Inc. logo

Icosavax, Inc.

ICVX

15.31 USD

Kezar Life Sciences, Inc. logo

Kezar Life Sciences, Inc.

KZR

0.576 USD

Utah Medical Products, Inc. logo

Utah Medical Products, Inc.

UTMD

67.22 USD

Talaris Therapeutics, Inc. logo

Talaris Therapeutics, Inc.

TALS

2.72 USD

Aadi Bioscience, Inc. logo

Aadi Bioscience, Inc.

AADI

1.87 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)